Jennifer Woyach, MD, on Relapsed/Refractory CLL: Next-Generation BTK Inhibitor

December 08, 2025 By The ASCO Post Staff

Jennifer Woyach, MD, of The Ohio State University Comprehensive Cancer Center, reviews phase I data on rocbrutinib, a new selective next-generation inhibitor of Bruton’s tyrosine kinase (BTK), in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) and prior exposure to BTK and/or BCL-2 inhibitors (Abstract 87). 

Related Content